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The mammary gland has unparalleled capacity to pro-
duce proteins. We have harnessed this potential to pro-
duce g/L levels of recombinant proteins in milk. Using
the beta casein promoter to drive expression of target
proteins, kg quantities can be obtained from each goat
during a normal lactation. For the past 20 years, we
have produced recombinant versions of human serum
proteins, (i.e. Antithrombin, Alpha-1 Antitrypsin, Alpha
Fetoprotein, Human Serum Albumin, FactorVII).
The technology has also allowed the production of
high levels of monoclonal antibodies (Mabs). These
included contracts for some innovator companies to
produce their antibody candidates. However, to move
into the follow-on biologics arena, we have generated
lines to produce our own versions of adalimumab, tras-
tuzumab, cetuximab, etanercept and a Mab to CD20.
Lactating goat lines are currently producing levels that
range from 2g/L to the trastuzumab line at 40g/L.
Taking advantage of the unique glycosylation proper-
ties of the mammary gland, we have found that some of
these antibodies have increased effector functions. In
addition, the centuximab produced does not contain the
alpha-1,3 gal present on the commercial product.
This capacity for production coupled with the reduced
capital requirement and freedom from expression
patents enable a new generation of biologicals
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